Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase

American Journal of Medicine

Volumn 120, Issue 8, 2007, Pages 706-712

  Dale, Krista M ^a,c,d   White, C Michael ^a,c,d   Henyan, Nickole N ^a,c,d   Kluger, Jeffrey ^b,c   Coleman, Craig I ^a,c,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c Section of Cardiology   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Creatine kinase; HMG CoA reductase inhibitor; Safety; Statin; Transaminase

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL RESEARCH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC HETEROGENEITY; HEART INFARCTION; HUMAN; HYDROPHILICITY; INCIDENCE; LIPOPHILICITY; MALE; PRIORITY JOURNAL; PUBLISHING; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS;

CREATINE KINASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER FUNCTION TESTS; LOVASTATIN; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN; TRANSAMINASES;

EID: 34547559566     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.07.033     Document Type: Article

References (20)

1. Cannon C.P., Braunwald E., McCave C., et al. Intensive versus moderate lipid lowering with statin after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 352 (2005) 1425-1435
3. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 7 (1986) 177-188
4. Naylor A.F. Small sample considerations in combining 2×2 tables. Biometrics 23 (1967) 349-356
5. Jadad A.R., DPhil R., Moore A., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials 17 (1996) 1-12
6. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1957) 719-748
7. deLemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 292 (2004) 1307-1316
8. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 206 (2002) 2055-2060
9. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
10. Raggi P., Davidson M., Callister T.Q., et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 112 (2005) 563-571
11. Post-CABG: The Post Coronary Artery Bypass Graft Trial Investigators. the effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 336 (1997) 153-162
12. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blinded, trial. Lancet 357 (2001) 577-581
13. Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction, the IDEAL Study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
14. Tamai I., Nezu J., Uchino H., et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273 (2000) 251-260
15. McTavish D., and Sorkin E.M. Pravastatin: a review of its pharmacologic properties and therapeutic potential in hypercholesterolemia. Drugs 42 (1991) 65-89
16. Negre-Aminou P., Van Vliet A.K., Van Erck M., et al. Inhibition of proliferation of human smooth muscle cells by various HMG CoA reductase inhibitors: comparison with other human cell types. Biochemica et Biophysica Acta 1345 (1997) 259-268
17. Newman C., Szarek M., Luo D., et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97 (2006) 61-67
18. White C.M. A review of pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42 (2002) 963-970
19. White C.M., and Chow M.S.S. A review of HMG CoA reductase inhibitors. US Pharmacist 23 (1998) H19-HS30
20. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540